- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Lite Strategy, Inc.(LITS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LITS
11/13/2026: LITS (1-star) is currently NOT-A-BUY. Pass it for now.
Lite Strategy is a micro-cap hybrid entity combining a legacy clinical-stage oncology pipeline with a digital asset treasury strategy centered on Litecoin. The company's primary strength lies in its debt-free balance sheet and substantial holdings of Litecoin acquired through strategic capital deployment, which drive quarterly net income via fair-value adjustments. Its main investment story hinges on acting as a public proxy for Litecoin appreciation while retaining optionality from drug candidates like voruciclib. However, risks include extreme price volatility, zero core operating revenue, and high sensitivity to cryptocurrency market fluctuations. This stock suits speculative or momentum-oriented investors willing to monitor crypto market dynamics and regulatory developments closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth potential relies entirely on cryptocurrency treasury appreciation and speculative capital inflows rather than core business expansion. |
| Momentum investor | Strong fit while signal remains positive | High volatility and price sensitivity to Litecoin movements create short-term trading momentum opportunities. |
| Value investor | Weak fit | The absence of stable operating cash flows and reliance on digital asset fair-value accounting complicate traditional valuation metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for treasury and operational needs. |
| Low-risk investor | Weak fit | Extreme price volatility, micro-cap liquidity risks, and crypto exposure make it unsuitable for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences sharp daily swings driven by cryptocurrency market sentiment and micro-cap trading dynamics. |
| Valuation risk | High | Valuation fluctuates disconnectively from traditional operational earnings due to heavy reliance on token fair-value marks. |
| Competition risk (Digital asset treasury competition) | Medium / high | The company competes with alternative digital asset holding vehicles and other crypto-treasury proxies for investor capital. |
| Business quality | Low | The lack of core commercial product revenue limits traditional operational business quality indicators. |
| Dividend income | Low / none | No dividend distributions are offered or anticipated. |
| Execution risk | High | Management must successfully execute its treasury strategy and navigate clinical or out-licensing decisions for legacy assets. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.30M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 328.0K shares | Beta 0.04 | 52 Weeks Range 0.69 - 2.08 | Updated Date 11/15/2026 |
52 Weeks Range 0.69 - 2.08 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.38 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -1.67% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Digital Asset Treasury Strategy | Holding and managing Litecoin (LTC) reserves, resulting in balance sheet gains or losses based on token market price movements. | Earnings and net income will heavily fluctuate based on crypto market prices rather than traditional sales. |
| Pharmaceutical Development | Legacy oncology drug candidates like voruciclib and zandelisib, which may generate future value through licensing or commercialization. | This segment currently generates no product sales and functions primarily as a legacy pipeline. |
Valuation
Trailing PE - | Forward PE 4.62 | Enterprise Value 20.76M | Price to Sales(TTM) 0.31 |
Enterprise Value 20.76M | Price to Sales(TTM) 0.31 | ||
Enterprise Value to Revenue 0.81 | Enterprise Value to EBITDA 2.38 | Shares Outstanding 29.88M | Shares Floating 27.72M |
Shares Outstanding 29.88M | Shares Floating 27.72M | ||
Percent Insiders 1.46 | Percent Institutions 17.91 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

